Chapelin F, Gedaly R, Sweeney Z, Gossett L
Mol Imaging Biol. 2021; 24(2):208-219.
PMID: 34708396
DOI: 10.1007/s11307-021-01648-3.
Gray M, Meehan J, Turnbull A, Martinez-Perez C, Kay C, Pang L
Front Vet Sci. 2020; 7:598338.
PMID: 33282935
PMC: 7688625.
DOI: 10.3389/fvets.2020.598338.
Jalota A, Kumar M, Das B, Yadav A, Chosdol K, Sinha S
Oncotarget. 2018; 9(26):18351-18366.
PMID: 29719610
PMC: 5915077.
DOI: 10.18632/oncotarget.24839.
Li M, Gonon G, Buonanno M, Autsavapromporn N, de Toledo S, Pain D
Antioxid Redox Signal. 2013; 20(9):1501-23.
PMID: 24111926
PMC: 3936510.
DOI: 10.1089/ars.2013.5649.
Kirkpatrick J, Rabbani Z, Bentley R, Hardee M, Karol S, Meyer J
Biomark Insights. 2009; 3:45-55.
PMID: 19578493
PMC: 2688355.
DOI: 10.4137/bmi.s570.
Hypoxia and radiation therapy: past history, ongoing research, and future promise.
Rockwell S, Dobrucki I, Kim E, Marrison S, Vu V
Curr Mol Med. 2009; 9(4):442-58.
PMID: 19519402
PMC: 2752413.
DOI: 10.2174/156652409788167087.
Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis.
Hardee M, Kirkpatrick J, Shan S, Snyder S, Vujaskovic Z, Rabbani Z
Br J Cancer. 2005; 93(12):1350-5.
PMID: 16288305
PMC: 2361536.
DOI: 10.1038/sj.bjc.6602846.
Vascular microenvironment in gliomas.
Vajkoczy P, Menger M
J Neurooncol. 2001; 50(1-2):99-108.
PMID: 11245285
DOI: 10.1023/a:1006474832189.
Intravital fluorescence videomicroscopy to study tumor angiogenesis and microcirculation.
Vajkoczy P, Ullrich A, Menger M
Neoplasia. 2000; 2(1-2):53-61.
PMID: 10933068
PMC: 1531866.
DOI: 10.1038/sj.neo.7900062.
Hypoxia induces p53 accumulation in the S-phase and accumulation of hypophosphorylated retinoblastoma protein in all cell cycle phases of human melanoma cells.
Danielsen T, Hvidsten M, Stokke T, Solberg K, Rofstad E
Br J Cancer. 1998; 78(12):1547-58.
PMID: 9862563
PMC: 2063247.
DOI: 10.1038/bjc.1998.722.
Regulation of cell proliferation under extreme and moderate hypoxia: the role of pyrimidine (deoxy)nucleotides.
Amellem O, Loffler M, Pettersen E
Br J Cancer. 1994; 70(5):857-66.
PMID: 7947090
PMC: 2033531.
DOI: 10.1038/bjc.1994.411.
Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide.
Law M, Hirst D, Brown J
Br J Cancer. 1981; 44(2):208-18.
PMID: 7272187
PMC: 2010739.
DOI: 10.1038/bjc.1981.172.
Low concentrations of misonidazole counteract effects of extreme hypoxia on cells in S.
Pettersen E, Lindmo T
Br J Cancer. 1981; 43(3):355-66.
PMID: 7013776
PMC: 2010604.
DOI: 10.1038/bjc.1981.56.
Inhibition of cell-cycle progression by acute treatment with various degrees of hypoxia: modifications induced by low concentrations of misonidazole present during hypoxia.
Pettersen E, Lindmo T
Br J Cancer. 1983; 48(6):809-17.
PMID: 6652020
PMC: 2011554.
DOI: 10.1038/bjc.1983.271.
Tumor hypoxia: its impact on cancer therapy.
Moulder J, Rockwell S
Cancer Metastasis Rev. 1987; 5(4):313-41.
PMID: 3552280
DOI: 10.1007/BF00055376.
Differential protective effects of varying degrees of hypoxia on the cytotoxicities of etoposide and bleomycin.
Yamauchi T, Raffin T, Yang P, Sikic B
Cancer Chemother Pharmacol. 1987; 19(4):282-6.
PMID: 2439223
DOI: 10.1007/BF00261473.
